NK PHARM HOLDINGS LIMITED

Abreviated accounts

31 July 2013

WEDNESDAY

18

23/04/2014 COMPANIES HOUSE

#31

NK PHARM HOLDINGS LIMITED

REPORT AND FINANCIAL STATEMENTS 2013

CONTENTS	Page
Balance sheet	3
Notes to the accounts	4 & 5

BALANCE SHEET 31 July 2013

	Note		2013		2012
FIXED ASSETS		£	£	£	£
Investments	3		-		-
CURRENT ASSETS					
Cash at bank and in hand					
		-		-	
CREDITORS: amounts falling due within one year	4				
NET CURRENT LIABILITIES					
TOTAL ASSETS LESS CURRENT LIABILITIES	}		-		-
CREDITORS:amounts falling due after one year	5				
NET ASSETS			-		- ==
CAPITAL AND RESERVES					
Called up share capital	6		444		444
Share premium			199,800		199,800
Profit and loss account			(200,244)		(200,244)
TOTAL EQUITY SHAREHOLDERS' FUNDS			-		-

For the year ended 31 July 2013 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies

Directors' responsibilities

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476, and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and with the Financial Reporting Standard for Smaller Entities (effective April 2008)

These abbreviated accounts of NK Pharm Holdings Limited, registered number 06954508, were approved by the Board of Directors on 16th April 2014

Signed on behalf of the Board of Directors

M Glynn Director

3

NOTES TO THE ACCOUNTS Year ended 31 July 2013

1. ACCOUNTING POLICIES

The principal accounting policies adopted are summarised below. They have been applied consistently throughout the current and preceding year

Basis of accounting

The financial statements are prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008)

Consolidation

The company is a parent company of a small group, subject to the small companies regime. In accordance with S398 of the Companies Act 2006 it has not prepared group accounts

Investments

Investments are stated at cost less any provision for impairment

Taxation

Current tax is provided at amounts expected to be paid using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events that result in an obligation to pay more tax in the future or a right to pay less tax in the future have occurred at the balance sheet date. Timing differences are differences between the company's taxable loss/profit and its results as stated in the financial statements that arise from the inclusion of gains and losses in tax assessment in periods different from those in which they are recognised in the financial statements.

A net deferred tax asset is regarded as recoverable and therefore recognised only to the extent that, on the basis of all available evidence, it can be regarded as more likely than not that there will be suitable taxable profits from which the future reversal of the underlying timing differences can be deducted

Deferred tax is measured at the average tax rates that are expected to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the balance sheet date. Deferred tax is measured on a non-discounted basis

NK PHARM HOLDINGS LIMITED

NOTES TO THE ACCOUNTS Year ended 31 July 2013

2. TURNOVER AND PRE-TAX PROFIT

Turnover represents amounts derived from the provision of goods and services which fall within the company's ordinary activities after deduction of trade discounts and value added tax and is recognised upon delivery. The turnover and pre-tax loss principally arise in the United Kingdom

3. INVESTMENTS

			£
	Cost and net book value as at 1 August 2012		-
	Disposal in year Net book value as at 31 July 2013		
	1.00 000 m 1.00 m 0 m 0 m 0 m 0 m 0 m 0 m 0 m 0 m 0	-	
	The company was sold on 1st September 2011 to Davison (Chemist) Limited It has	s not traded sine	ce this date
4.	CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR		
		2013	2012
		£	£
	Bank loan	-	_
			=======================================
5.	CREDITORS: AMOUNTS FALLING DUE AFTER ONE YEAR		
		2013	2012
		£	£
	Bank loan	-	-
			=======================================
_	CALLED UP CHADE CADITAL		
6.	CALLED UP SHARE CAPITAL		
		2013 £	2012 £
	Called up, allotted and fully paid	x.	L
	444 ordinary shares of £1 each	444	444

7. ULTIMATE CONTROLLING PARTY

The company is controlled by the directors